Recognition of the importance of embolization in atherosclerotic vascular disease

Circulation

Volumn 101, Issue 5, 2000, Pages 570-580

  Topol, Eric J ^a   Yadav, Jay S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Embolization; Imaging

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN;

ACUTE HEART INFARCTION; ARTIFICIAL EMBOLISM; ATHEROSCLEROSIS; CORONARY REPERFUSION; FIBRINOLYTIC THERAPY; HEART CATHETER; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; ST SEGMENT; STROKE; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VASCULAR SURGERY;

EID: 0034620537     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.5.570     Document Type: Review

References (77)

1. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation. 1986;73:418-427.
2. Frink RJ, Rooney PA Jr, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J. 1988;59:196-200.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part 1. N Engl J Med. 1992;326:242-250. Review.
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, part 2. N Engl J Med. 1992;326:310-318. Review.
5. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92:1701-1709.
6. Frink RJ, Ostrach LH, Rooney PA, Rose J. Coronary thrombosis, ulcerated atherosclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: a large autopsy study. J Clin Invest. 1990;2:199-210.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
8. Douglas JS Jr. Percutaneous intervention inpatients with prior coronary bypass surgery. In: Topol EJ, ed. Textbook of Interventional Cardiology. 3rd ed. Philadelphia, Pa: WB Saunders; 1999:297-316.
9. Yadav JS, Roubin GS, Iyer S, Vitek J, King P, Jordan WD, Fisher WS. Elective stenting of the extracranial carotid arteries. Circulation. 1997; 95:376-381.
10. Yao S-K, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand J-P, Campbell WB, Buja LM, Willerson JT. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992;70:39-48.
11. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685-691.
12. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest. 1989;84:18-27.
13. Willerson JT, Cohen LS, Maseri A. Pathophysiology and clinical recognition. In: Willerson JT, Cohn JN, eds. Cardiovascular Medicine. New York, NY: Churchill Livingston; 1995:333-365.
14. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignet-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. 1999;93: 2951-2958.
15. Eguchi H, Ikeda H, Murohara T, Yasukawa H, Haramaki N, Sakisaka S, Imaizumi T. Endothelial injuries of coronary arteries distal to thrombotic sites: role of adhesive interaction between endothelial P-selectin and leukocyte sialyl LewisX. Circ Res. 1999;84:525-535.
16. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-228.
17. Wu K, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JAC. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772.
18. Jordan WD Jr, Voellinger DC, Doblar DD, Plyushcheva NP, Fisher WS, McDowell HA. Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy. Cardiovasc Surg. 1999;7:33-38.
19. Koch K-C, vom Dahl J, Kleinhans E, Klues HG, Radke PW, Ninnemann S, Schulz G, Buell U, Hanrath P. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. J Am Coll Cardiol. 1999;33:998-1004.
20. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler G, Berdan LG, Hinohara T. Califf RM, for the CAVEAT Study Group. A comparison of coronary angioplasty with directional atherectomy in patients with coronary artery disease. N Engl J Med. 1993;329:221-227.
21. Holmes DR, Topol EJ, Califf RM, Leya F, Berberg PB, Talley JD, Kellett MA, Shani J, Gottlieb RS, Whitlow PL, Adelman AG, Pinkerton CA, Lee KL, Pieper K, Keeler GP, Ellis SG, for the CAVEAT-II Investigators. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. Circulation. 1995;91:1966-1974.
22. Abdelmeguid AE, Topol EJ. The myth of the myocardial "infarctlet" during percutaneous coronary revascularization procedures. Circulation. 1996;94:3369-3375.
23. Elliott JM, Berdan LG, Holmes DR, Isner JM, King SB, Keeler GP, Kearney M, Califf RM, Topol EJ, for the CAVEAT Study Investigators. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). Circulation. 1995;91:2158-2166.
24. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528-1536.
25. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131:1097-1105.
26. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA. 1997;277:461-466.
27. Califf RM, Abdelmeguid A, Kuntz R, Popma JJ, Tardiff BE, Crenshaw B, Bauman RP, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky R, Granger CB, Harrington RA, Zuckerman B. Chaitman BR, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241-251.
28. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Berdan LG, O'Hanesian MA, Keeler GP, Garrett K, Ohman EM, Mark DM, Jacobs AK, Topol EJ, for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol. 1995;25:1693-1699.
29. Adgey AAJ, Mathew TP, Harbinson MT. Periprocedural creatine kinase-MB elevations: long-term impact and clinical implications. Clin Cardiol. 1999;22:257-265.
30. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Wang AL, Anderson KM, Califf RM, for the EPIC Investigators. Long term protection from myocardial ischemic events after brief integrin b3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
31. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-1696.
32. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ, for the EPILOG Investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Circulation. 1999;99:1951-1958.
33. EPISTENT Investigators. Randomised controlled trial to assess safety of coronary stenting with use of abciximab. Lancet. 1998;352:85-90.
34. Ravkilde J, Nissen H, Mickley H, Andersen PE, Thayssen P, Horder M. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J. 1994;127:13-20.
35. Johansen O, Brekke M, Stromme JH, Valen V, Seljeflot I, Skjaeggestad O, Arnesen H. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J. 1998;19:112-117.
36. Reimers B, Lachin M, Cacciovillani L, Secchiero S, Ramondo A, Isabella G, Marzari A, Zaninotto M, Plebani M, Chioin R, Maddalena F, Dalla-Volta S, Troponin T, creatine kinase MB mass, and creatine kinase MB isoform ratio in the detection of myocardial damage during non-surgical coronary revascularization. Int J Cardiol. 1997;60:7-13.
37. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
38. Hamm CW, Heeschen C, Goldman B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML, for the CAPTURE Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340: 1623-1629.
39. Carlino M, De Gregorio J, Di Mario C, Anzuini A, Airoldi F, Albiero R, Briguori C, Dharmadhikari A, Sheiban I, Colombo A. Prevention of distal embolization during saphenous vein graft lesion angioplasty: experience with a new temporary occlusion and aspiration system. Circulation. 1999;99:3221-3223.
40. Neumann F-J, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stems in acute myocardial infarction. Circulation. 1998;98:2695-2701.
41. 3 and GPIIb-IIIa blockers: past, present and future perspectives. Lancet. 1999;353: 227-231.
42. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995; 91:2151-2157.
43. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
44. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ, for the RAPPORT Investigators. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998; 98:734-741.
45. PURSUIT Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. N Engl J Med. 1998;339:436-443.
46. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina: the PARAGON study. Circulation. 1998;97:2386-2395.
47. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338: 1498-1505.
48. The PRISM-PLUS Study Investigators. Inhibition of the platelet glyco-protein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med. 1998;338:1488-1497.
49. Kong DF, Califf RM, Miller DP, Moliterno DJ, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829-2835.
50. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30: 1193-1199.
51. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999; 33:654-660.
52. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
53. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
54. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855-860.
55. Gaspardone A, Crea F, Versaci F, Tomai F, Pellegrino A, Chiariello L, Gioffre PA. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998; 82:515-518.
56. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI-11A substudy. J Am Coll Cardiol. 1998;31: 1460-1465.
57. Stefanidis C, Diamantopoulos L, Vlachopoulos C, Tsiamis E, Dernellis J, Toutouzas K, Stefanadi E, Toutouzas P. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation. 1999;99:1965-1971.
58. BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation. 1997;96:1761-1769.
59. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, Topol EJ. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarction. J Am Coll Cardiol. 1998;32:1366-1370.
60. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ, for the EPIC Investigators. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol. 1997; 80:985-988.
61. Hammon JW Jr, Stump DA, Kon ND, Cordell AR, Hudspeth AS, Oaks TE, Brooker RF, Rogers AT, Hilbawi R, Coker LH, Troost BT. Risk factors and solutions for the development of neurobehavioral changes after coronary artery bypass grafting. Ann Thorac Surg. 1997;63: 1613-1618.
62. Clark RE, Brillman J, Davis DA, Lovell MR, Price TR, Magovern GJ. Microemboli during coronary artery bypass grafting: genesis and effect on outcome. J Thorac Cardiovasc Surg. 1995;109:249-257; discussion 257-258.
63. Taggart DP, Bhattacharya K, Meston N, Standing SJ, Kay JD, Pillai R, Johnsson P, Westaby S. Serum S-100 protein concentration after cardiac surgery: a randomized trial of arterial line filtration. Eur J Cardiothorac Surg. 1997;11:645-649.
64. Barbut D, Yao FS, Lo YW, Silverman R, Hager DN, Trifiletti RR, Gold JP. Determination of size of aortic emboli and embolic load during coronary artery bypass grafting. Ann Thorac Surg. 1997;63:1262-1267.
65. Hornick P, Smith PL, Taylor KM. Cerebral complications after coronary bypass grafting. Curr Opin Cardiol. 1994;9:670-679.
66. Kronzon I, Tunick PA. Atheromatous disease of the thoracic aorta: pathologic and clinical implications. Ann Intern Med. 1997;126: 629-637.
67. Selnes OA, Goldsborough MA, Borowicz LM, McKhann GM. Neurobehavioural sequelae of cardiopulmonary bypass. Lancet. 1999;353: 1601-1606.
68. van Gijn J. Thrombolysis in ischemic stroke: double or quits? Circulation. 1996;93:1616-1617.
69. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomized, double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
70. Choudhri TF, Hoh BL, Zerwas H-G, Prestigiacomo CJ, Kim SC, Connolly ES, Kottirsch G, Pinsky DJ. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102: 1301-1310.
71. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GHJ, Masaryk TJ, Perl J II. Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIb/IIIa receptor inhibitor. Am J Neuroradiol. 1997;18: 1257-1260.
72. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, Overlie PA, Linnemeier TJ, Moses J, O'Neill WW, Grines CL, on behalf of the Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty in acute myocardial infarction at experienced centers: the PAMI study group experience. J Intervent Cardiol. 1999;12: 101-108.
73. Rosenschein U. Ultrasound thrombolysis: an alternative to the pharmacological approach. J Intervent Cardiol. 1998;11:603-607.
74. Topol EJ. Towards a new frontier in myocardial reperfusion therapy. Circulation. 1998;97:211-218.
75. The Strategies for Patency Enhancement in the Emergency Department (SPEED, GUSTO-IV Pilot) Group. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. In press.
76. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht H-J, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. Circulation. 1999;99:2720-2732.
77. Ohman EM, Kleinman NS, Gacioch G, Worley SJ, Navetta FI, Talley D, Anderson HV, Ellis SG, Cohen M, Sprigg D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon RM, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators. Combined accelerated tissue plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrelin in acute myocardial infarction: results of a randomized, placebo controlled dose-ranging trial. Circulation. 1997;95:846-854.